Krystal Biotech Valuation
| KRYS Stock | USD 164.10 0.32 0.20% |
At this time, the firm appears to be fairly valued. Krystal Biotech secures a last-minute Real Value of $166.55 per share. The latest price of the firm is $164.1. Our model forecasts the value of Krystal Biotech from analyzing the firm fundamentals such as Current Valuation of 4.16 B, profit margin of 0.60 %, and Return On Equity of 0.0887 as well as examining its technical indicators and probability of bankruptcy. In general, most investors recommend acquiring undervalued stocks and selling overvalued stocks since, at some point, asset prices and their ongoing real values will merge together. Key fundamental drivers impacting Krystal Biotech's valuation include:
Price Book 5.8311 | Enterprise Value 4.2 B | Enterprise Value Ebitda 68.4458 | Price Sales 48.7477 | Forward PE 181.8182 |
Fairly Valued
Today
Please note that Krystal Biotech's price fluctuation is very steady at this time. Calculation of the real value of Krystal Biotech is based on 3 months time horizon. Increasing Krystal Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Krystal Biotech is useful when determining the fair value of the Krystal stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Krystal Biotech. Since Krystal Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Krystal Stock. However, Krystal Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 164.1 | Real 166.55 | Target 150.44 | Hype 163.31 |
The real value of Krystal Stock, also known as its intrinsic value, is the underlying worth of Krystal Biotech Company, which is reflected in its stock price. It is based on Krystal Biotech's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Krystal Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Krystal Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Krystal Biotech helps investors to forecast how Krystal stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Krystal Biotech more accurately as focusing exclusively on Krystal Biotech's fundamentals will not take into account other important factors: Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Krystal Biotech's intrinsic value based on its ongoing forecasts of Krystal Biotech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Krystal Biotech's closest peers. When choosing an evaluation method for Krystal Biotech, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.
Krystal Biotech Investments |
|
Krystal Valuation Trend
Knowing Krystal Biotech's actual value is paramount for traders to make sound investment determinations. Krystal Biotech's real value is not only important for the investor to make better decisions but also for a more accurate overall view of Krystal Biotech's financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Krystal Biotech's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.
Krystal Market Cap
Krystal Biotech is currently regarded as number one stock in market capitalization category among related companies. Market capitalization of Health Care industry is now estimated at about 200.28 Billion. Krystal Biotech holds roughly 4.69 Billion in market capitalization claiming about 2.34% of equities under Health Care industry.Krystal Biotech Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Krystal Biotech's current stock value. Our valuation model uses many indicators to compare Krystal Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Krystal Biotech competition to find correlations between indicators driving Krystal Biotech's intrinsic value. More Info.Krystal Biotech is currently regarded as number one stock in price to earning category among related companies. It is currently regarded as number one stock in price to book category among related companies . Price To Book Ratio is likely to drop to 4.11 in 2024. Comparative valuation analysis is a catch-all model that can be used if you cannot value Krystal Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Krystal Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Krystal Biotech's earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Krystal Biotech's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Krystal Biotech and how it compares across the competition.
About Krystal Biotech Valuation
The stock valuation mechanism determines the current worth of Krystal Biotech on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Krystal Biotech. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Krystal Biotech based exclusively on its fundamental and basic technical indicators. By analyzing Krystal Biotech's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Krystal Biotech's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Krystal Biotech. We calculate exposure to Krystal Biotech's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Krystal Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 42.6 M | 44.7 M | |
| Pretax Profit Margin | 0.23 | 0.24 | |
| Operating Profit Margin | (1.73) | (1.81) | |
| Net Profit Margin | 0.19 | 0.20 | |
| Gross Profit Margin | 0.76 | 0.67 |
8 Steps to conduct Krystal Biotech's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Krystal Biotech's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Krystal Biotech's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Krystal Biotech's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Krystal Biotech's revenue streams: Identify Krystal Biotech's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Krystal Biotech's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Krystal Biotech's growth potential: Evaluate Krystal Biotech's management, business model, and growth potential.
- Determine Krystal Biotech's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Krystal Biotech's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Krystal Biotech Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Krystal Biotech does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 27.8 M | |
| Forward Price Earnings | 181.8182 |
Krystal Biotech Current Valuation Indicators
Valuation refers to the process of determining the present value of Krystal Biotech and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Krystal we look at many different elements of the entity such as Krystal's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Krystal Biotech's valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Krystal Biotech's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Krystal Biotech, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Krystal Biotech's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Krystal Biotech's worth.When determining whether Krystal Biotech is a strong investment it is important to analyze Krystal Biotech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Krystal Biotech's future performance. For an informed investment choice regarding Krystal Stock, refer to the following important reports: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Krystal Stock analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |
Is Krystal Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Krystal Biotech. If investors know Krystal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Krystal Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 2.18 | Revenue Per Share 3.451 | Return On Assets (0.05) | Return On Equity 0.0887 |
The market value of Krystal Biotech is measured differently than its book value, which is the value of Krystal that is recorded on the company's balance sheet. Investors also form their own opinion of Krystal Biotech's value that differs from its market value or its book value, called intrinsic value, which is Krystal Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Krystal Biotech's market value can be influenced by many factors that don't directly affect Krystal Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Krystal Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Krystal Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Krystal Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.